361 results on '"Malyszko, Jolanta"'
Search Results
2. Scope and Consistency of Cancer Outcomes Reported in Randomized Trials in Kidney Transplant Recipients
3. WCN24-418 DIALYSIS FLUID MANAGEMENT – LET'S MAKE DIALYSIS GREENER
4. WCN24-2141 HOW DOES THE USE OF CONTINUOUS GLUCOSE MONITORING DIFFER AMONG PEOPLE WITH ESKD AFTER KIDNEY TRANSPLANTATION, ON HEMODIALYSIS, AND ON PERITONEAL DIALYSIS?
5. Drugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease.
6. Range and Consistency of Cardiovascular Outcomes Reported by Clinical Trials in Kidney Transplant Recipients: A Systematic Review
7. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
8. Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
9. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
10. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation
11. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer
12. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
13. How to assess kidney function in oncology patients
14. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review
15. Effect of time-dependent dialysate bicarbonate concentrations on acid–base and uremic solute kinetics during hemodialysis treatments.
16. Methodological challenges and biases in the field of cognitive function among patients with chronic kidney disease
17. Iron status and anemia control are related to peritoneal membrane properties in peritoneally dialyzed patients
18. Cardiovascular Outcomes Reported in Hemodialysis Trials
19. #5547 SERUM PERIOSTIN IN KIDNEY TRANSPLANT RECIPIENTS AS A NOVEL BIOMARKER PREDICTING RENAL FUNCTION LOSS
20. Green dialysis – let us talk about dialysis fluid.
21. Medical Waste Management: How Industry Can Help Us Protect the Environment and Money: PUB094
22. Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients.
23. Prevalence of cognitive impairment in peritoneal dialysis patients and associated factors
24. Range and Consistency of Cardiovascular Outcomes Reported by Clinical Trials in Kidney Transplant Recipients: A Systematic Review
25. Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?
26. Potassium management with finerenone: Practical aspects
27. Chronic Kidney Disease Prevalence in Patients with Colorectal Cancer Undergoing Surgery
28. Main Barriers to the Introduction of a Home Haemodialysis Programme in Poland: A Review of the Challenges for Implementation and Criteria for a Successful Programme
29. MO658: Effect of a Time-Dependent Dialysate Bicarbonate Concentration on Intradialytic and Postdialytic Blood Bicarbonate Kinetics
30. MO656: Validity of the Hydrogen Ion Mobilization Model During Haemodialysis with Time-Dependent Dialysate Bicarbonate Concentrations
31. Biomarkers of iron metabolism in chronic kidney disease
32. Influence of formalized Predialysis Education Program (fPEP) on the chosen and definitive renal replacement therapy option
33. Cognitive Impairment and Kidney Transplantation: Underestimated, Underrecognized but Clinically Relevant Problem
34. Acute kidney injury prevalence in patients with colorectal cancer undergoing surgery with curative intent
35. Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in CKD: translational opportunities and challenges
36. The fate of triaged and rejected manuscripts
37. Current Status of Renal Anemia Pharmacotherapy—What Can We Offer Today
38. Renal Replacement Modality Affects Uremic Toxins and Oxidative Stress
39. Potential Effects of Immunosuppression on Oxidative Stress and Atherosclerosis in Kidney Transplant Recipients
40. Uremic Toxins, Oxidative Stress, Atherosclerosis in Chronic Kidney Disease, and Kidney Transplantation
41. Post-Contrast Acute Kidney Injury in Patients with Various Stages of Chronic Kidney Disease—Is Fear Justified?
42. MO128RETINOL BINDING PROTEIN (RBP) - NEW BIOMARKER OF KIDNEY INJURY IN MULTIPLE MYELOMA PATIENTS*
43. High-resolution computed tomography rather than chest radiography – how pandemic changed our evaluation policy of potential kidney transplant recipients
44. The Serum Concentration of Anti-Aging Proteins, Sirtuin1 and αKlotho in Patients with End-Stage Kidney Disease on Maintenance Hemodialysis
45. Erratum to: Hematological disorders following kidney transplantation
46. Iron and Chronic Kidney Disease: Still a Challenge
47. Haematological disorders following kidney transplantation
48. Fluvastin therapy affects TAFI concentration in kidney transplant recipients
49. Iron status in patients with chronic heart failure
50. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.